Side effects come from the molecule, not the vendor. Nausea, vomiting, constipation and diarrhea dominate the labeled adverse reaction tables for every product in this class regardless of who prescribed it. What differs between these three services is monitoring: who reviews baseline labs, how fast a clinician responds when a symptom appears, and whether anyone is watching between refills.
Medically reviewed by Dr. Mudit Arora, MD, Internal Medicine
What the approved labels actually warn about
The prescribing information for these products is public on DailyMed, and it is more specific than most marketing pages. Products in the class carry a boxed warning concerning thyroid C-cell tumors observed in rodents, together with contraindications for personal or family history of medullary thyroid carcinoma and for multiple endocrine neoplasia syndrome type 2. The Foundayo label states that orforglipron itself is not pharmacologically active in rats or mice and did not produce tumors in rodents, which is a distinction worth reading rather than assuming.
Beyond the boxed section, the warnings run consistently across products: acute pancreatitis with instruction to discontinue if suspected, severe gastrointestinal reactions with a note that use is not recommended in severe gastroparesis, acute gallbladder disease with follow-up indicated if cholecystitis is suspected, monitoring for progression in patients with a history of diabetic retinopathy, and pulmonary aspiration during general anesthesia or deep sedation, with instruction to tell healthcare providers about planned surgeries or procedures.
That last one is the item most often missed. A member scheduled for a colonoscopy or elective surgery needs the prescriber and the anesthesia team informed, and a program that never asks about upcoming procedures will not surface it.
Monitoring is where the three services diverge
Calibrate’s published sequence puts laboratory work early: blood work at a lab during the first week, results reviewed by a clinician in a video visit around days seven to fourteen, and a recurring cadence of short one-to-one coaching sessions across a program running past twelve months. The coaching contact is not a clinical visit, but it is a repeating human touchpoint where a tolerability problem is likely to be mentioned out loud.
Ro publishes ongoing provider support with one-to-one messaging, regular check-ins, dose adjustment help and lab testing where clinically indicated, framing side effect management as part of the membership rather than a separate service. Hims and Hers similarly runs clinical support around the prescription, with its program terms published on its own site.
The practical question for any of them is response time when something goes wrong at 9pm on a Saturday. Ask what the stated turnaround is for a clinical message, whether a licensed clinician or a support agent reads it first, and what triggers an escalation. Those answers are checkable before signup and rarely appear in comparison charts.
How plainly a service explains these risks upfront is itself a signal. Providers such as HealthRX publish a standalone GLP-1 side effects overview, Ro and Hims and Hers describe adverse reactions inside their intake flows, and LillyDirect points patients back to the approved label, so a careful reader can see how each one handles the uncomfortable part before entering payment details. Reading that material next to the DailyMed label is a fast way to check whether a program is summarizing fairly or softening the warnings.
The compounded pathway adds a separate monitoring burden
Compounded semaglutide and compounded tirzepatide are pharmacy preparations that the FDA has not reviewed for safety, effectiveness or manufacturing quality, and the agency has published concerns specific to unapproved GLP-1 products, including the fact that different salt forms are different active ingredients. A published case series described administration errors involving compounded semaglutide reported to a poison control center, and a pharmacovigilance analysis of adverse event reports involving compounded GLP-1 products has since appeared in the safety literature. Dosing presented in units or volume rather than in a prefilled pen is a large part of why those errors happen.
None of that makes supervision impossible, and it does raise what supervision has to cover. Among cash-pay compounded programs, several publish the dispensing pharmacy and the supervising clinical model up front, including Henry Meds, Mochi Health and FormBlends, which at least lets a buyer ask concrete questions about who is accountable for a dosing instruction. Hims and Hers stated in March 2026 that it would offer compounded GLP-1 access only where a provider determines it is clinically necessary for a limited set of customers whose needs cannot be met by commercially available options.
| Monitoring element | Coaching and navigation model | Medication-first telehealth | Question to ask |
|---|---|---|---|
| Baseline labs | Blood work expected in the first week | Ordered where clinically indicated | Which panel, and who reviews the result |
| First clinician contact | Video visit reviewing lab results | Asynchronous review or scheduled visit | Whether a live visit is included or optional |
| Between-refill contact | Recurring short coaching sessions | Messaging and periodic check-ins | Who reads the first message, clinician or agent |
| Symptom escalation | Coach routes clinical issues onward | Care team messaging thread | Stated response time and after-hours path |
| Dose reduction for tolerability | Handled at clinical review points | Handled through dose adjustment support | Whether a lower dose changes the price |
| Procedure and surgery flagging | Depends on intake and visit questions | Depends on intake and visit questions | Whether anyone asks about upcoming procedures |
Tolerability is the main reason people stop
Gastrointestinal effects are usually worst during titration and often ease at a stable dose, which is why dose escalation pace is a tolerability decision rather than a scheduling formality. Real-world analyses of GLP-1 therapy show a large share of patients discontinuing within the first year, and reviews published in 2026 examine the causes and consequences of stopping in detail. A program that reflexively pushes toward the next dose step, or that prices higher doses more attractively, is applying pressure in the wrong direction for someone who is struggling.
Ask directly whether the clinician will hold a member at a lower dose indefinitely if that dose is tolerable and working. The answer reveals how the program handles the most common real-world scenario in this category.
Frequently asked questions
Are side effects worse with one of these services?
No, because the adverse reaction profile is a property of the drug and the dose. What a program can influence is how quickly a dose is escalated, how fast someone reaches a clinician when symptoms appear, and whether a dose reduction is offered before a member simply quits. Those are service differences, not pharmacological ones.
Is baseline blood work necessary before starting?
Prescribers order it for good reasons, including establishing kidney and liver status, screening for diabetes and setting a comparison point for later changes. One of these programs builds a lab draw into the first week by default and others order testing where clinically indicated, so the honest difference is whether testing is standard or discretionary.
What symptoms warrant contacting a prescriber immediately?
Severe or persistent abdominal pain, especially radiating to the back, along with persistent vomiting, signs of dehydration, or symptoms suggesting gallbladder trouble. Labels instruct discontinuation if pancreatitis is suspected and clinical follow-up if cholecystitis is suspected, which is why reaching a clinician quickly matters more than any convenience feature.
Does the prescriber need to know about a planned surgery?
Yes. Current labeling in this class notes pulmonary aspiration during general anesthesia and deep sedation and instructs patients to inform healthcare providers about planned procedures. Anyone with an endoscopy, dental sedation or elective surgery on the calendar should raise it well ahead of the date, with both the prescriber and the procedural team.
